# Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

> **NCT02603107** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 578 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** RTV
- **DRUG:** ATV
- **DRUG:** DRV
- **DRUG:** COBI
- **DRUG:** ATV/co
- **DRUG:** DRV/co
- **DRUG:** FTC/TDF
- **DRUG:** ABC/3TC
- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT02603107
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-20
- **Primary completion:** 2017-05-15
- **Final completion:** 2019-12-23
- **Target enrollment:** 578 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603107, "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02603107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*